Amid new government directives around diversity, equity, and inclusion programs in the US, our April issue explores the pivots and adjustments pharma and healthcare interests are making to maintain the progress of such efforts in advancing clinical research.
ACT: How important is it for CROs to form strong relationships with sites, especially in the rare disease space? Lwoff: If the CRO has a […]
Image credit: peterschreiber.media | stock.adobe.com. The FDA has granted Priority Review status to a supplemental Biologics License Application (sBLA) submitted by Regeneron Pharmaceuticals and Sanofi […]
Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about: Specific challenges women with chronic illnesses […]